Community Research and Development Information Service - CORDIS

Specific challenge: Antibiotic resistance is a global problem. It is considered by the World Health Organization as one of the three greatest threats to human health for the next decades. In Europe, however, research on the resistance to antibiotics and on how to make sustainable use of antibiotics is fragmented. In addition, few countries have specific programs dedicated to this field of research.


The Joint Programming Initiative (JPI) on Anti-Microbial Resistance (AMR) provides an excellent opportunity for joint research of the EU Member States addressing the emerging problem of antibiotic resistance in human and veterinary medicine. Indeed, the currently funded research projects in national or trans-national programs are usually the result of calls initiated within other research areas rather than from research programmes specifically focusing on AMR. Consequently, the variable and non-permanent resources of trans-national organisations and individual countries are insufficient to provide the long-term funding opportunities that are required to solve the major research questions concerning AMR. In addition, research activities on AMR are not harmonised between countries; which may lead to duplications in the research being performed in different countries.


The 19 participating countries of the AMR JPI aim to accomplish the coordination of European research on AMR in close collaboration with the funding instruments of the EU; specifically Horizon 2020, Innovative Medicines Initiative (IMI) and the ERA-NET Infect-ERA.


This will create the necessary critical mass and develop the most advanced scientific approaches to tackle the problem of AMR, reversing its increasing trend, in the way forward defined by the Strategic Research Agenda which is to be adopted by the JPIAMR in early 2014.


This transnational cooperation will enhance the societal impact that is required in this area, promoting knowledge dissemination among multiple sectors of the society that are implicated – patients, clinical, veterinarians, pharmacists, food producers and representatives of the pharmaceutical industry.


Scope: Proposals should be central to the effective coordination of joint research funding in the area of AMR. Proposals should coordinate national and regional programmes in order to implement the Strategic Research Agenda (SRA) of the JPI AMR through a transnational call with EU co-funding resulting in grants to third parties.


This transnational call topic should be in line with one or more of the priority areas of the SRA and is expected to lead to a lower, smarter use of antibiotics in veterinary and clinical settings and to a significant reduction of the risk that antibiotic-resistance poses to public health.


Proposal should implement other joint activities including collaborative actions with the World Health Organisation or the pharmaceutical industry (among others) as well as additional joint international calls without EU co-funding (e.g. with Canada).


The Commission considers that proposals requesting a contribution from the EU of a minimum of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.


Expected impact:


•                    Leverage transnational research by funding research proposals on a topic identified by the JPIAMR from its Strategic Research Agenda and implementation plan.

•                    Stimulate and increase research into the causes, prevention, diagnosis and treatment of infections caused by resistant organisms and force the EU added value in the area of antibiotics.

•                    Enhancement and/or better exploitation of current research funding activities at national, European and international level.

•                    Catalysing and strengthening the development of national and trans-national strategies in JPI AMR countries.

•                    Establishment and alignment of existing national strategies.

•                    Increased visibility, also at a political level, of the burden of AMR and the benefits of research to economy and society.


Type of action: ERA-NET Co-fund

Record Number: 665217 / Last updated on: 2015-03-25
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top